Prion-like characteristics of the bacterial protein Microcin E492

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Shahnawaz, Mohammad ^a   Park, Kyung Won ^a   Mukherjee, Abhisek ^a   Diaz Espinoza, Rodrigo ^a   Soto, Claudio ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOCIN; MICROCIN; PROTEIN AGGREGATE;

CELL CULTURE; CHEMISTRY; ESCHERICHIA COLI; METABOLISM; PRION; PROTEIN CONFORMATION;

BACTERIOCINS; CELLS, CULTURED; ESCHERICHIA COLI; PRIONS; PROTEIN AGGREGATES; PROTEIN CONFORMATION;

EID: 85016611081     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep45720     Document Type: Article

References (55)

1. Griffith, J. S. Self-replication and scrapie. Nature 215, 1043-1044 (1967).
2. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
3. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519-550 (2001).
4. Prusiner, S. B. Prions. Proc. Natl. Acad. Sci. USA 95, 13363-13383 (1998).
5. Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4, 49-60 (2003).
6. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366 (2006).
7. Soto, C., Estrada, L. & Castilla, J. Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem. Sci. 31, 150-155 (2006).
8. Soto, C. Transmissible proteins: expanding the prion heresy. Cell 149, 968-977 (2012).
9. Jarrett, J. T. & Lansbury, P. T. Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73, 1055-1058 (1993).
10. Wickner, R. B. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566-569 (1994).
11. Lindquist, S. Mad cows meet psi-chotic yeast: the expansion of the prion hypothesis. Cell 89, 495-498 (1997).
12. Wickner, R. B., Edskes, H. K., Maddelein, M. L., Taylor, K. L. & Moriyama, H. Prions of yeast and fungi. Proteins as genetic material. J. Biol. Chem. 274, 555-558 (1999).
13. Derkatch, I. L., Bradley, M. E., Hong, J. Y. & Liebman, S. W. Prions affect the appearance of other prions: the story of [PIN(+)]. Cell 106, 171-182 (2001).
14. Nakayashiki, T., Kurtzman, C. P., Edskes, H. K. & Wickner, R. B. Yeast prions [URE3] and [PSI +] are diseases. Proc. Natl. Acad. Sci. USA 102, 10575-10580 (2005).
15. Eaglestone, S. S., Cox, B. S. & Tuite, M. F. Translation termination efficiency can be regulated in Saccharomyces cerevisiae by environmental stress through a prion-mediated mechanism. EMBO J. 18, 1974-1981 (1999).
16. True, H. L. & Lindquist, S. L. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 407, 477-483 (2000).
17. Halfmann, R., Alberti, S. & Lindquist, S. Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol. 20, 125-133 (2010).
18. Si, K., Lindquist, S. & Kandel, E. R. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 115, 879-891 (2003).
19. Hou, F. et al. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 146, 448-461 (2011).
20. de Lorenzo, V. Isolation and characterization of microcin E492 from Klebsiella pneumoniae. Arch. Microbiol. 139, 72-75 (1984).
21. de Lorenzo, V., Martinez, J. L. & Asensio, C. Microcin-mediated interactions between Klebsiella pneumoniae and Escherichia coli strains. J. Gen. Microbiol. 130 (Pt 2), 391-400 (1984).
22. Destoumieux-Garzon, D. et al. Microcin E492 antibacterial activity: evidence for a TonB-dependent inner membrane permeabilization on Escherichia coli. Mol. Microbiol. 49, 1031-1041 (2003).
23. de Lorenzo, V. & Pugsley, A. P. Microcin E492, a low-molecular-weight peptide antibiotic which causes depolarization of the Escherichia coli cytoplasmic membrane. Antimicrob. Agents Chemother. 27, 666-669 (1985).
24. Lagos, R., Wilkens, M., Vergara, C., Cecchi, X. & Monasterio, O. Microcin E492 forms ion channels in phospholipid bilayer membrane. FEBS Lett. 321, 145-148 (1993).
25. de Lorenzo, V. Factors affecting microcin E492 production. J. Antibiot. 38, 340-345 (1985).
26. Corsini, G., Baeza, M., Monasterio, O. & Lagos, R. The expression of genes involved in microcin maturation regulates the production of active microcin E492. Biochimie 84, 539-544 (2002).
27. Bieler, S. et al. Amyloid formation modulates the biological activity of a bacterial protein. J. Biol. Chem. 280, 26880-26885 (2005).
28. Ghetti, B. et al. Prion protein amyloidosis. Brain Pathol. 6, 127-145 (1996).
29. Yang, H., Yang, S., Kong, J., Dong, A. & Yu, S. Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy. Nat. Protoc. 10, 382-396 (2015).
30. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
31. Lorenzo, A. & Yankner, B. A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247 (1994).
32. Porat, Y., Abramowitz, A. & Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des 67, 27-37 (2006).
33. Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005).
34. Caughey, B., Raymond, G. J., Kocisko, D. A. & Lansbury, P. T., Jr. Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J. Virol. 71, 4107-4110 (1997).
35. Li, L. & Lindquist, S. Creating a protein-based element of inheritance. Science 287, 661-664 (2000).
36. Osherovich, L. Z., Cox, B. S., Tuite, M. F. & Weissman, J. S. Dissection and design of yeast prions. PLoS. Biol. 2, E86 (2004).
37. Chernoff, Y. O., Lindquist, S. L., Ono, B., Inge-Vechtomov, S. G. & Liebman, S. W. Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. Science 268, 880-884 (1995).
38. Ferreira, P. C., Ness, F., Edwards, S. R., Cox, B. S. & Tuite, M. F. The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation. Mol. Microbiol. 40, 1357-1369 (2001).
39. Jung, G. & Masison, D. C. Guanidine hydrochloride inhibits Hsp104 activity in vivo: a possible explanation for its effect in curing yeast prions. Curr. Microbiol. 43, 7-10 (2001).
40. Patino, M. M., Liu, J. J., Glover, J. R. & Lindquist, S. Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. Science 273, 622-626 (1996).
41. Tagliavini, F., Forloni, G., D'Ursi, P., Bugiani, O. & Salmona, M. Studies on peptide fragments of prion proteins. Adv. Protein Chem. 57, 171-201 (2001).
42. Holscher, C., Delius, H. & Burkle, A. Overexpression of nonconvertible PrPc delta114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. J. Virol. 72, 1153-1159 (1998).
43. Caughey, B. & Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
44. Kane, M. D. et al. Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J. Neurosci. 20, 3606-3611 (2000).
45. Meyer-Luehmann, M. et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006).
46. Morales, R., Duran-Aniotz, C., Castilla, J., Estrada, L. D. & Soto, C. De novo induction of amyloid-beta deposition in vivo. Mol. Psychiatry 17, 1347-1353 (2012).
47. Rymer, D. L. & Good, T. A. The role of prion peptide structure and aggregation in toxicity and membrane binding. J. Neurochem. 75, 2536-2545 (2000).
48. Ettaiche, M., Pichot, R., Vincent, J. P. & Chabry, J. In vivo cytotoxicity of the prion protein fragment 106-126. J. Biol. Chem. 275, 36487-36490 (2000).
49. Brown, D. R. PrPSc-like prion protein peptide inhibits the function of cellular prion protein. Biochem. J. 352 Pt 2, 511-518 (2000).
50. Chabry, J., Caughey, B. & Chesebro, B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273, 13203-13207 (1998).
51. Soto, C. et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 355, 192-197 (2000).
52. Shahnawaz, M. & Soto, C. Microcin amyloid fibrils A are reservoir of toxic oligomeric species. J. Biol. Chem. 287, 11665-11676 (2012).
53. Wray, W., Boulikas, T., Wray, V. P. & Hancock, R. Silver staining of proteins in polyacrylamide gels. Anal. Biochem. 118, 197-203 (1981).
54. LeVine, H. III Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410 (1993).
55. Mayr-Harting, A., Hedges, A. J. & Berkeley, R. C. W. Methods for studying bacteriocins. Methods Microbiol. 7A, 315-422 (1972).